TP53 and adenocarcinoma: We selected four NSCLC lines, NCI H460 a large cell carcinoma and A549 adenocarcinoma which are both wildtype for ATM and p53, and H23 adenocarcinoma that is ATM-deficient and possess the M246I p53 mutation which results in low p53 protein expression levels and loss of function (34,35).